| The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation |
25 |
| The American Brachytherapy Society consensus statement on intraoperative radiation therapy |
14 |
| Increasing age predicts poor cervical cancer prognosis with subsequent effect on treatment and overall survival |
14 |
| Proficiency-based cervical cancer brachytherapy training |
13 |
| Brachytherapy: A critical component of primary radiation therapy for cervical cancer: From the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS) |
12 |
| Compendium of fractionation choices for gynecologic HDR brachytherapy-An American Brachytherapy Society Task Group Report |
11 |
| Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy |
10 |
| Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy |
9 |
| High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results |
9 |
| Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial results |
8 |
| Accelerated partial breast irradiation for suitable elderly women using a single fraction of multicatheter interstitial high-dose-rate brachytherapy: Early results of the Single-Fraction Elderly Breast Irradiation (SiFEBI) Phase I/II trial |
8 |
| Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103 |
8 |
| Efficacy and safety of iodine-125 radioactive seeds brachytherapy for advanced non-small cell lung cancer-A meta-analysis |
8 |
| Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing |
7 |
| Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial |
7 |
| The American Brachytherapy Society consensus statement for electronic brachytherapy |
7 |
| Workflow and efficiency in MRI-based high-dose-rate brachytherapy for cervical cancer in a high-volume brachytherapy center |
7 |
| Understanding the underutilization of cervical brachytherapy for locally advanced cervical cancer |
6 |
| Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complications |
6 |
| Image-guided interstitial high-dose-rate brachytherapy for locally recurrent uterine cervical cancer: A single-institution study |
6 |
| Improving dose delivery by adding interstitial catheters to fixed geometry applicators in high-dose-rate brachytherapy for cervical cancer |
6 |
| Malignant obstructive jaundice treated with intraluminal placement of Iodine-125 seed strands and metal stents: An analysis of long-term outcomes and prognostic features |
6 |
| Outcomes of choroidal melanomas treated with eye physics plaques: A 25-year review |
6 |
| Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) |
5 |
| Improved rectal dosimetry with the use of SpaceOAR during high-dose-rate brachytherapy |
5 |
| Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer |
5 |
| Time-resolved in vivo dosimetry for source tracking in brachytherapy |
5 |
| Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer |
5 |
| Efficacy and the toxicity of the interstitial high-dose-rate brachytherapy in the management of recurrent keloids: 5-year outcomes |
5 |
| Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone |
4 |
| Appropriate timing for postimplant imaging in permanent breast seed implant: Results from a serial CT study |
4 |
| The impact of adjuvant vaginal brachytherapy in women with Stage II uterine endometrioid carcinoma: Results of a National Cancer Database analysis |
4 |
| Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients |
4 |
| Standardization and automation of quality assurance for high-dose-rate brachytherapy planning with application programming interface |
4 |
| A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer |
4 |
| Evaluation of bi-objective treatment planning for high-dose-rate prostate brachytherapy-A retrospective observer study |
4 |
| A risk-based approach to development of ultrasound-based high-dose-rate prostate brachytherapy quality management |
4 |
| High-dose-rate brachytherapy as monotherapy for prostate cancer: The impact of cellular repair and source decay |
4 |
| An integrated system for clinical treatment verification of HDR prostate brachytherapy combining source tracking with pretreatment imaging |
4 |
| Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities |
4 |
| The role of radiation therapy in the treatment of Stage II endometrial cancer: A large database study |
3 |
| Iodine-125 seed brachytherapy inhibits non-small cell lung cancer by suppressing epithelial-mesenchymal transition |
3 |
| Endobronchial brachytherapy-A novel approach for the management of airway amyloidosis |
3 |
| I-125 seed implantation for hepatocellular carcinoma with portal vein tumor thrombus: A systematic review and meta-analysis |
3 |
| National patterns of care for early-stage penile cancers in the United States: How is radiation and brachytherapy utilized? |
3 |
| A machine-learning-based prediction model of fistula formation after interstitial brachytherapy for locally advanced gynecological malignancies |
3 |
| Long-term outcomes of APBI via multicatheter interstitial HDR brachytherapy: Results of a prospective single-institutional registry |
3 |
| Derivation of in vivo source tracking error thresholds for TRUS-based HDR prostate brachytherapy through simulation of source positioning errors |
3 |
| MRI-based treatment planning and dose delivery verification for intraocular melanoma brachytherapy |
3 |
| Brachytherapy patient safety events in an academic radiation medicine program |
3 |
